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Abstract
Background: Small intestinal bacterial overgrowth (SIBO) is a condition in which excessive levels of bacteria,
mainly the colonic-type species are present in the small intestine. Recent data suggest that SIBO may contribute to
the pathophysiology of Irritable bowel syndrome (IBS). The purpose of this study was to identify potential
predictors of SIBO in patients with IBS.
Methods: Adults with IBS based on Rome II criteria who had predominance of bloating and flatulence underwent
a glucose breath test (GBT) to determine the presence of SIBO. Breath samples were obtained at baseline and at
30, 45, 60, 75 and 90 minutes after ingestion of 50 g of glucose dissolved in 150 mL of water. Results of the
glucose breath test, which measures hydrogen and methane levels in the breath, were considered positive for
SIBO if 1) the hydrogen or methane peak was >20 ppm when the baseline was <10 ppm, or 2) the hydrogen or
methane peak increased by 12 ppm when baseline was ≥10 ppm.
Results: Ninety-eight patients were identified who underwent a GBT (mean age, 49 y; 78% female). Thirty-five
patients (36%) had a positive GBT result suggestive of SIBO. A positive GBT result was more likely in patients >55
years of age (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.4-9.0) and in females (OR, 4.0; 95% CI, 1.1-14.5).
Hydrogen was detected more frequently in patients with diarrhea-predominant IBS (OR, 8; 95% CI, 1.4-45), and
methane was the main gas detected in patients with constipation-predominant IBS (OR, 8; 95% CI, 1.3-44). There
was no significant correlation between the presence of SIBO and the predominant bowel pattern or concurrent
use of tegaserod, proton pump inhibitors, or opiate analgesics.
Conclusions: Small intestinal bacterial overgrowth was present in a sizeable percentage of patients with IBS with
predominance of bloating and flatulence. Older age and female sex were predictors of SIBO in patients with IBS.
Identification of possible predictors of SIBO in patients with IBS could aid in the development of successful
treatment plans.
Background
Irritable bowel syndrome (IBS) is the most commonly
diagnosed chronic functional gastrointestinal (GI) disor-
der and has an estimated prevalence of 10% to 15% in
North America [1]. Irritable bowel syndrome affects
females approximately twice as often as males and is
most frequently diagnosed in individuals between the
ages of 30 and 50 years [1,2]. Symptoms of IBS can sub-
stantially impact patients’ quality of life, and the effect
of IBS on physical and psychological health can nega-
tively impact the workplace [3-5]. Results of a large US
survey (N = 5430) showed that individuals with IBS
missed substantially more workdays per year (mean,
13.4 days) compared with individuals without a func-
tional GI disorder (mean, 4.9 days) [6]. Thus, the eco-
nomic burden of IBS in the United States is substantial
and includes estimated direct costs (eg, physician visits)
of $1.7 to $10 billion annually and estimated indirect
costs (eg, employee absenteeism) of up to $20 billion
annually [7].
Irritable bowel syndrome is characterized by abdom-
inal discomfort associated with altered bowel habits
including constipation, diarrhea, or alternating periods
of constipation and diarrhea. Additional symptoms of
IBS may include abdominal bloating and flatulence, but
specific GI symptoms often vary among patients. The
pathophysiologic mechanisms contributing to IBS are
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gests that small intestinal bacterial overgrowth (SIBO)
may contribute to IBS pathophysiology [8]. Small intest-
inal bacterial overgrowth involves abnormal growth (ie,
>10
5 colony forming units/mL) of endogenous bacteria
in the small intestine resembling those normally found
in the colon [9,10]. A potential link between SIBO and
IBS has been suggested by symptom similarities (eg,
abdominal discomfort, bloating, and flatulence) [8,11,12]
and by the reported prevalence of SIBO in patients with
IBS [13-17]. In studies using lactulose or glucose breath
testing, SIBO was detected in up to 84% (Range 4-84%)
of patients who met Rome I [15,17] or Rome II
[13,14,16] criteria for IBS. Furthermore, results from
multiple clinical studies have shown that treatment with
antibiotics can reduce or eradicate SIBO [14,15,17-22]
and improve symptoms of IBS [15,17,18,21-24], evidence
that further supports the role of SIBO in IBS. Published
clinical data evaluating characteristics associated with
SIBO in patients with IBS are lacking. Therefore, the
purpose of this clinical study was to identify potential
predictors of SIBO occurrence in patients with IBS with
predominance of bloating and flatulence.
Methods
Patients ≥ 18 years of age who met Rome II criteria for
IBS who had predominance of bloating and flatulence
and referred to the Functional Bowel Diseases clinic at a
tertiary care University Medical center supervised by
one of the investigators (RWM) between 2004 and 2006
were included in the study. The Human Subjects Com-
mittee at the Kansas University Medical Center
approved the study. Individuals with predisposing condi-
tions for SIBO (eg, diabetes mellitus, scleroderma, prior
small intestinal surgery) were excluded. Demographic
data, predominant bowel habit pattern, and concurrent
use of opiate analgesics, tegaserod, and proton pump
inhibitors (PPIs) were recorded at study entry. Patients
were subcategorized as having diarrhea-predominant
IBS (IBS-D), constipation-predominant IBS (IBS-C), or
alternating IBS (IBS-A) based on predominant bowel
habits.
Patients who had taken systemic antibiotics or anti-
fungals in the previous month were excluded from
breath testing. All other patients with IBS with predomi-
nance of bloating and flatulence underwent a glucose
breath test (GBT) at study entry. Patients were required
to have a low carbohydrate meal the evening before test-
ing and to fast for ≥12 hours before testing. Smoking
and physical exercise were not allowed 1 hour before
the test was administered. Immediately before the GBT,
patients used a mouthwash containing 40 mL of 1%
chlorhexidine. Two breath samples were obtained at
baseline and at 30, 45, 60, 75, and 90 minutes following
ingestion of 50 g of glucose dissolved in 150 mL of
water. The baseline and post-glucose ingestion peak
values for hydrogen and methane were recorded for
each patient, and the total excretion of hydrogen and
methane was calculated as an area-under-time concen-
tration curve. Expiratory breath samples were obtained
using a commercial device (GaSampler; QuinTron
Instrument Company, Milwaukee, Wisconsin) to con-
firm sampling of alveolar gas. This device allows the
separation of the initial 500 mL of dead space air from
the remaining alveolar air collected in a gas-tight bag.
Samples were analyzed immediately after collection. Gas
chromatography (Model DP; QuinTron Instrument
Company, Milwaukee, Wisconsin) was employed to
measure the concentration in parts per million (ppm) of
hydrogen and methane in the air. The breath test result
was considered positive for SIBO if: 1) the hydrogen or
methane peak was >20 ppm when baseline was <10
ppm or, 2) the hydrogen or methane peak increased by
>12 ppm when baseline was ≥10 ppm.
Logistic regression was employed for statistical analy-
sis and odds ratios (OR) with 95% confidence intervals
(CI) were calculated for comparisons of a positive breath
test result with sex, previous and current use of IBS
medication(s), and predominant bowel habits.
Results
A total of 169 patients (25 male) who met the Rome II
criteria for IBS were evaluated in the Functional Bowel
Disease clinic during the study period. Ninety eight (76
female) of these patients had bloating and flatulence as
the predominant symptoms and underwent testing for
SIBO with a GBT. The mean age of patients in this
cohort was 49 years (range, 21-85 years; Table 1). Fifty-
one patients (52%) had IBS-C, 38 patients (39%) had
IBS-D, and 9 patients (9%) had IBS-A.
A subgroup of 35 patients (36%) was determined to
have SIBO based on a positive GBT result, of which the
majority of patients were female (n = 32; 91%). Glucose
breath testing was more likely to be positive in females
with IBS (OR, 4.0; 95% CI, 1.1-14.5; Table 1) and
patients >55 years of age (OR, 3.6; 95% CI, 1.4-9.0;
Table 1). Hydrogen was the predominant gas detected
i np a t i e n t sw i t hI B S - D( O R ,8 ;9 5 %C I ,1 . 4 - 4 5 ) ,a n d
methane was detected more frequently in patients with
IBS-C (OR, 8; 95% CI, 1.3-44). No significant correlation
was observed between the presence of SIBO in patients
with IBS and predominant bowel pattern and use of opi-
ate analgesics, tegaserod, or PPIs (Table 1). All patients
with a positive GBT were treated with antibiotics.
Discussion
Existing clinical evidence seems to suggest that SIBO
may contribute to the pathophysiology of IBS. However,
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detection method employed. In studies that included
lactulose or glucose breath testing, SIBO was detected
in up to 84% of patients who met Rome criteria for IBS
[13-17]. Because breath tests indirectly measure bacteria
and are associated with relatively low sensitivity and
specificity [10], many consider direct bacterial assess-
ment of intestinal aspirate cultures a better method of
detecting SIBO [8,9,25]. However, direct sampling also
has limitations, including lack of accessibility to the dis-
tal small intestine and potential for contamination dur-
ing sampling [25]. Clinical studies employing direct
sampling of jejunal aspirates detected SIBO in 4% to
12% of patients with IBS, a lower prevalence compared
with results of breath testing. The most accurate
method for detecting SIBO is the subject of much
debate [10,12,26]; however, results from clinical studies
evaluating SIBO in IBS have confirmed the presence of
SIBO in a subset of patients with IBS. Additionally,
reports that antibiotic therapy normalized breath test
results [14,15,17-22] and improved IBS symptoms
[15,17,18,21-24] provide support for the potential role of
bacteria in IBS. In our study, a positive GBT was seen
in 36% of patients with IBS-like symptoms, especially
those with predominance of bloating and flatulence.
This group had higher pre-test probability of SIBO,
because if the whole cohort of 169 patients are consid-
ered and if it is assumed that IBS patients without bloat-
ing or flatulence did not have SIBO, then the prevalence
of SIBO in IBS in our cohort seems to be lower at
around 21%.
The purpose of the present study was to identify spe-
cific characteristics that could serve as potential
predictors of the association of SIBO development in
patients with IBS and not to estimate the prevalence of
SIBO in IBS. The incidence of SIBO in our cohort was
higher than that reported by other groups who
employed the GBT method [26,27]. One explanation
could be that the patients who underwent GBT in our
study could be regarded as having a higher likelihood of
a positive test based on prominence of bloating and
flatulence in their symptom profile.
S i g n i f i c a n tf i n d i n g so ft h i ss t u d ya r et h a tp a t i e n t s> 5 5
years of age, females with IBS like symptoms, especially
those with prominence of bloating and flatulence are
more likely to have a positive GBT. Although there is
no previously published clinical evidence suggesting
SIBO is more common in females, substantially more
females than males are diagnosed with IBS accounting
for this difference [1,28]. Additionally, SIBO is more
prevalent in older individuals as suggested by prior stu-
dies [29-31], most likely as a result of reduced intestinal
motility with advancing age [32]. Alternatively, no speci-
fic bowel pattern was indicative of SIBO in the present
study, a surprising observation given that diarrhea has
previously been reported as the predominant bowel
habit in patients with SIBO [12]. Hydrogen was the pre-
dominant gas detected in patients with IBS-D and
methane was the gas detected in IBS-C, a finding
observed in prior studies.
Finally, no significant correlation was observed
between detection of SIBO in patients with IBS and pre-
vious or current use therapeutic agents such as opiate
analgesics, PPI’s, or tegaserod. This lack of correlation
was also unexpected given that opiate analgesics are
known to slow intestinal motility [33], which could
potentiate bacterial overgrowth; tegaserod therapy is
associated with substantial acceleration of small intest-
inal motility and hypothetically, could protect against
SIBO [34]; and long-term use of PPIs is theoretically
linked to the development of SIBO [35]. A recent article
also speculated that since IBS patients are more likely to
receive PPI therapy than healthy controls, they are more
likely to develop SIBO due to reduction of the gastric
acid barrier that prevents bacterial overgrowth in the
small bowel [36]. However, we did not find the associa-
tion between PPI use and a positive GBT in our study.
The duration of hypochlorhydria due to PPI’s is variable
and not sustained and this effect is unpredictable unless
PPI’s are reliably taken every day by the patient.
It could be pointed out that a sizeable number (38%)
of IBS patients in the study were taking opiate analge-
sics. The reason for this disproportionately high use of
narcotic analgesics is because our center is a referral
center for functional bowel disease and most of these
patients were being prescribed these agents prior to
referral to our center.
Table 1 Demographic and clinical characteristics of
patients with IBS and SIBO
Characteristics All patients
(N = 98)
IBS with SIBO
(n = 35)
Odds ratio*
(95% CI)
Age >55 y, n (%) 28 (29) 16 (46) 3.6 (1.4-9.0)
Female, n (%) 76 (78) 32 (91) 4.0 (1.1-14.5)
IBS subtype, n (%)
IBS-C 51 (52) 19 (54) 1.2 (0.5-2.6)
IBS-D 38 (39) 15 (43) 1.3 (0.6-3.0)
IBS-A 9 (9) 1 (3) 0.2 (0.02-1.7)
Medications,** n (%)
Tegaserod 15 (15) 6 (17) 1.1 (0.4-3.3)
Opiate
analgesic
38 (39) 13 (37) 1.0 (0.4-2.3)
Proton pump
inhibitor
21 (21) 7 (20) 0.8 (0.3-2.1)
IBS: irritable bowel syndrome; SIBO: small intestinal bacterial overgrowth; CI:
confidence interval; IBS-C: constipation-predominant IBS; IBS-D: diarrhea-
predominant IBS; IBS-A: alternating IBS.
*Comparing patients with IBS versus patients with IBS and SIBO, **Previous
and current use of specific IBS therapy.
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s t u d yb e i n gar e t r o s p e c t i v er e v i e w ,b )T h ep a t i e n t sw h o
underwent GBT testing for SIBO were not consecutive
patients and included only those with prominence of
bloating and flatulence, c) Lack of control arm and
absence of data regarding the rate of a positive GBT in
healthy controls, and d) Although we found that the
GBT was more likely to be positive in patients > 55
years, it is hard to explain whether this is a result of
advancing age or related to IBS. Certainly, the patients
seen at this tertiary setting had been evaluated by a
number of physicians in the past and had the diagnosis
of IBS for a number of years, hence SIBO could have
been present for some years, including when they were
much younger. One logical conclusion would be that
G B Ti sm o r el i k e l yt ob ep o s i t i v ei nap e r s o n> 5 5y e a r s
of age who has IBS like symptoms, especially those with
prominence of bloating and flatulence.
Conclusion
In summary, a significant percentage (36%) of patients
with IBS who have bloating and flatulence as their pre-
dominant complaint have a positive GBT suggestive of
SIBO. Older age and female sex seem to be predictors
for SIBO. The identification of characteristics specific to
the subgroup of patients with SIBO and IBS may pro-
vide further understanding of the pathophysiologic
mechanisms of IBS and contribute to the development
of successful treatment strategies.
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